How Nonprofits Rescue Shelved Rare Disease Drug Pipelines From Pharma

NewAmsterdam Pharma has dosed its first patient in the Phase 2b SPINOZA trial to evaluate Obicetrapib in adults with preclinical Alzheimer’s disease.

Clinical trials face major operational challenges in recruiting patients with rare, undiagnosed conditions due to a lack of diagnostic testing coverage.

Immix Biopharma announced an 89% complete response rate for its BCMA-targeted CAR-T cell therapy NXC-201 in a Phase 2 trial for relapsed AL amyloidosis.

The FDA has issued a second recall this year for thousands of bottles of Chlorthalidone blood pressure tablets because the pills do not dissolve properly.